Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in HELLP Syndrome
NCT04103489Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Feb 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eculizumab in HELLP syndrome (HELLP), sponsored by Johns Hopkins University. Primary endpoints: Change in Aspartate Aminotransferase at 72 hours, Change in Alanine Aminotransferase at 72 hours and 1 more. Started Feb 2021; status: completed.
02
Drugs
eculizumab
03
Conditions
HELLP syndrome (HELLP)
Beyond the preview
Go deeper on NCT04103489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04103489.